The Rheingold firm has recently filed two cases in New York federal courts for cancer victims after using Actos. These suits are against Takeda Pharmaceuticals America, Takeda Pharmaceuticals North America, Takeda Pharmaceutical Company and Eli Lilly. Lilly and Takeda created a joint sales collaboration in 1999. We allege that an initial animal study revealed drug-induced tumors in male rats. Further, the PROactive study in human users of Actos showed cases of bladder cancer, although the cancer cases were not reported in the published results. In the legal complaints our firm filed, we recount multiple broad medical studies which demonstrated that increased dosing resulted in a higher rate of bladder cancer, with statistical significance being in as short as one to two years.
We intend to vigorously pursue investigations as to why Takeda employees made statements that medical studies did not support a connection with bladder cancer, and why high level Takeda management decisions were made to delay any increased warnings with for Actos or recalling the drug outright. All this delay is in the face of independent medical studies which reported bladder cancer cases in Actos users in the immediate years after Actos was placed on the market. We will update the blog as litigation developments occur.
